Article
Endocrinology & Metabolism
Kunzhe Lin, Jianping Zhang, Yinghong Lin, Zhijie Pei, Shousen Wang
Summary: This study investigated the metabolic differences between invasive and non-invasive NFPAs and found distinct metabolite profiles. It also confirmed the high expression of the M2 macrophage marker in invasive NFPAs.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Hongyan Liu, Saichun Zhang, Ting Wu, Zhaohui Lv, Jianming Ba, Weijun Gu, Yiming Mu
Summary: This study found that the expression of CTSK varies in different invasion patterns of pituitary adenomas and may serve as a marker for tumor invasion, while MMP9 and MMP2 may be associated with different invasion types.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medical Laboratory Technology
Yuan Ren, Ying Wang, Xinjie Bao, Ming Feng, Bing Xing, Wei Lian, Yong Yao, Renzhi Wang
Summary: Incomplete surgical resection of invasive non-functional pituitary adenomas (NFPAs) carries a risk of subsequent complications. This study examined biomarkers for determining the invasiveness of NFPAs and explored therapeutic targets. The results highlighted the role of MMP1 in tumor invasion and angiogenesis, with exosomes playing a regulatory role.
CLINICA CHIMICA ACTA
(2022)
Article
Endocrinology & Metabolism
Giuseppe Giuffrida, Valeria D'Argenio, Francesco Ferrau, Vito Alessandro Lasorsa, Francesca Polito, Federica Aliquo, Marta Ragonese, Oana Ruxandra Cotta, Ylenia Alessi, Rosaria Oteri, Federica Di Maggio, Alessio Asmundo, Petronilla Daniela Romeo, Federica Spagnolo, Lucio Pastore, Filippo Flavio Angileri, Mario Capasso, Salvatore Cannavo, M'Hammed Aguennouz
Summary: The study found that there are complex epigenetic modifications, mainly methylation and miRNA activity, in pituitary adenomas. Nonfunctioning tumors (NFPAs) showed higher methylation levels compared to GH-omas, with 178 differentially methylated regions (DMRs) mainly located in noncoding and intronic sequences. Additionally, the study identified three hypermethylated genes involved in tumorigenesis processes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Xiao Yue, Fengming Lan, Weiping Liu
Summary: circDDX17 is downregulated in PA tissues and is associated with invasion, tumor size, and progression-free survival. Overexpression of circDDX17 significantly inhibits cell migration and invasion through miR-1279. CADM2 is a direct target of miR-1279 and silencing CADM2 reverses the tumor-suppressing effects of circDDX17. Our study demonstrates that circDDX17 upregulates CADM2 expression by sponging miR-1279, suppressing the invasive behaviors of PA.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Kaori Takeshita, Ichiro Abe, Wataru Kameda, Kota Ishii, Yuya Fujita, Mai Nagata, Kentaro Ochi, Yuki Senda, Midori Koga, Tadachika Kudo, Yurika Hada, Kaoru Takase, Yusuke Morinaga, Miiko Ito, Makiko Abe, Kenichi Ishizawa, Kunihisa Kobayashi
Summary: Pituitary apoplexy is a rare syndrome that often leads to spontaneous bleeding or infarction in pituitary tumors or glands. This study found that pituitary apoplexy occurs most frequently in patients with nonfunctional pituitary adenomas and is not related to tumor size. However, it is associated with hormonal deficiencies, liver dysfunction, hyponatremia or hypochloremia, and dyslipidemia.
Article
Oncology
John Alexander, Odette Mariani, Celine Meaudre, Laetitia Fuhrmann, Hui Xiao, Kalnisha Naidoo, Andrea Gillespie, Ioannis Roxanis, Anne Vincent-Salomon, Syed Haider, Rachael Natrajan
Summary: This study found that invasive lobular breast cancers with heterogeneous E-cadherin expression are composed of different components with a common ancestor. CDH1 gene mutations and loss of E-cadherin protein expression are characteristic of these tumors. Regardless of E-cadherin protein expression, these tumors should be considered part of the spectrum of invasive lobular breast cancers.
Article
Oncology
Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer
Summary: The expression of PD-L1 is associated with proliferative grades of Trouillas' classification and specific subtypes of PitNET expressing growth hormone.
Article
Endocrinology & Metabolism
Zhiyu Xi, Pamela S. Jones, Masaaki Mikamoto, Xiaobin Jiang, Alexander T. Faje, Chuansheng Nie, Kathryn E. Labelle, Yunli Zhou, Karen K. Miller, Roy J. Soberman, Xun Zhang
Summary: Aggressive pituitary adenomas have increased expression of PD-L2, CD80, and CD86 compared to normal pituitary glands, and significantly higher levels of CD80 and CD86 compared to non-aggressive tumors. These findings support further research on the potential role of immune checkpoint inhibition therapy in the treatment of pituitary adenomas.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Sherwin Tavakol, Michael P. Catalino, David J. Cote, Xian Boles, Edward R. Laws, Wenya Linda Bi
Summary: A novel classification scheme for cystic sellar lesions based on the heterogeneity of the cyst wall/contents and the presence of a solid component on imaging was proposed. The study found that different types of cysts were associated with the diagnoses of Rathke cleft cyst and cystic pituitary adenoma, with higher cyst types, fluid-fluid level presence, symptomatic hyperprolactinemia, and obesity being predictors of cystic pituitary adenoma.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Qizhi Zhang, Ying Wang, Yinting Zhou, Qiujuan Zhang, Chuan Xu
Summary: The abnormal expression of miRNAs has been closely linked to tumor development. This study found significantly lower levels of miRNA-26b, miRNA-138, miRNA-206, and miRNA-let-7e in the peripheral serum of NFPA patients compared to normal subjects. These miRNAs may play a role in the occurrence and progression of NFPAs, providing a basis for further exploration of tumor markers in pituitary adenomas.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Junyi Fu, Yanli Li, Lisha Wu, Xin Yang, Tingting Quan, Xi Li, Jiamin Zeng, Yinhui Deng, Jinxiu Yu
Summary: This study aimed to investigate the incidence, risk factors, and prognosis of pituitary hemorrhage in pituitary adenomas treated with gamma knife radiosurgery. It was found that nonfunctioning pituitary adenomas were an independent risk factor for new or worsened pituitary hemorrhage after gamma knife radiosurgery.
Article
Clinical Neurology
Kelin Chen, Guoge Li, Xixiong Kang, Pinan Liu, Lingye Qian, Yijun Shi, Rasha Alsamani Osman, Zhijun Yang, Guojun Zhang
Summary: This study aimed to investigate noninvasive methods to discover viable biomarkers for assessing the invasiveness of pituitary adenomas. Through analyzing E-cadherin, N-cadherin, Epcam, TGF-beta, Smad3, and Smad7 in tissues and exosomes, the results suggested that EMT-related biomarkers in serum exosomes could potentially be used for assessing the invasiveness of pituitary adenomas.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Pathology
Soudeh Ghafouri-Fard, Farzaneh Abbasi, Amir Nicknam, Bashdar Mahmud Hussen, Solat Eslami, Nader Akbari Dilmaghani, Mohammad Taheri, Guive Sharifi
Summary: Pituitary adenomas are slow-growing tumors with dysregulation of lncRNAs, including PVT1 and NEAT1, which play important roles in regulating cell functions. In this study, higher expression levels of NEAT1 were found in pituitary adenoma tissues, especially non-functioning pituitary adenoma samples. However, the sensitivity values and AUC values of PVT1 and NEAT1 were not adequate for distinguishing non-functioning pituitary adenomas from non-cancerous tissues.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Review
Endocrinology & Metabolism
Mengqi Chang, Shenzhong Jiang, Xiaopeng Guo, Jun Gao, Peng Liu, Xinjie Bao, Ming Feng, Renzhi Wang
Summary: Exosomes are small vesicles that carry various molecules, including RNAs, and play important roles in cell communication and drug delivery. In this review, the impact of exosomal RNAs on pituitary adenoma and their potential as clinical therapies are discussed. Potential biomarkers and therapeutic applications of exosomes in pituitary adenoma are examined.
FRONTIERS IN ENDOCRINOLOGY
(2023)
